NCT00293202 - Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

June 30, 2010

Conditions

End Stage Renal Disease

Interventions

DRUG

Etanercept

Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week

DRUG

Placebo

Hemodialysis patients will receive Saline by subcutaneous injection twice a week

Trial Locations (1)

University of California, Davis, Medical Center, Sacramento